In a press release, the Waltham company said it requested a priority review for the supplemental application and if granted by the Food and Drug Administration, it would mean a six month review timeline.
The supplemental application is "based on the positive results from a recent phase 3 study assessing the efficacy and safety of Vivitrol for opioid dependence," the company said.
As an opioid treatment, Vivitrol would be administered once a month by injection. In 2006, the FDA approved Vivitrol as a treatment for alcohol dependence. To read some previous Globe and Globe wire services coverage of Alkermes and Vivitrol, please click here.